Edition:
United States

Cyclacel Pharmaceuticals Inc (CYCC.OQ)

CYCC.OQ on NASDAQ Stock Exchange Capital Market

3.19USD
1:21pm EST
Change (% chg)

$-0.73 (-18.62%)
Prev Close
$3.92
Open
$3.90
Day's High
$3.90
Day's Low
$3.19
Volume
16,768
Avg. Vol
25,805
52-wk High
$9.72
52-wk Low
$3.19

CYCC.OQ

Chart for CYCC.OQ

About

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor... (more)

Overall

Beta: 3.04
Market Cap(Mil.): $16.66
Shares Outstanding(Mil.): 4.25
Dividend: --
Yield (%): --

Financials

  CYCC.OQ Industry Sector
P/E (TTM): -- 44.08 29.63
EPS (TTM): -4.08 -- --
ROI: -63.42 -3.35 12.96
ROE: -65.01 5.80 14.11

Cyclacel's leukemia drug for elderly patients fails in key study

Cyclacel Pharmaceuticals Inc said its lead experimental drug did not help elderly patients with acute myeloid leukemia live longer in a late-stage study.

Feb 23 2017

UPDATE 1-Cyclacel's leukemia drug for elderly patients fails in key study

Feb 23 Cyclacel Pharmaceuticals Inc said its lead experimental drug did not help elderly patients with acute myeloid leukemia live longer in a late-stage study.

Feb 23 2017

Cyclacel's leukemia drug for elderly patients fails in key study

Feb 23 Cyclacel Pharmaceuticals Inc said its experimental drug failed in a late-stage study on patients aged 70 years or more with newly diagnosed acute myeloid leukemia.

Feb 23 2017

BRIEF-Cyclacel reports top-line results from phase 3 study in patients with acute myeloid leukemia

* Cyclacel announces top-line results from pivotal phase 3 seamless study in elderly patients with acute myeloid leukemia

Feb 23 2017

BRIEF-Intra-Cellular Therapies' unit enters into supply agreement with Siegfried Evionnaz

* Intra-Cellular Therapies Inc- on January 4, 2017, co's unit entered into a supply agreement with Siegfried Evionnaz SA- SEC filing Source: (http://bit.ly/2jALlxx) Further company coverage:

Jan 10 2017

BRIEF-Cyclacel Pharmaceuticals Q3 loss per share $0.86

* Cyclacel pharmaceuticals reports 3rd quarter 2016 financial results

Nov 14 2016

BRIEF-Intra-Cellular Therapies reports Q3 financial results

* Intra-Cellular Therapies reports third quarter 2016 financial results and provides corporate update

Nov 09 2016

BRIEF-Tang Capital reports 9.5 pct stake in Cyclacel Pharmaceuticals

Source text - http://bit.ly/2cDs1vi Further company coverage:

Sep 16 2016

BRIEF-Intra-Cellular Therapies files for mixed shelf of up to $350 mln

* Files for mixed shelf of up to $350 million - SEC filing Source: (http://bit.ly/2c1aXOy) Further company coverage:

Sep 02 2016

More From Around the Web

Competitors

Earnings vs. Estimates